Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
Status:
Completed
Trial end date:
2017-10-06
Target enrollment:
Participant gender:
Summary
An Open-label extension (OLE), expanded access study, to assess long-term safety of
SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in
patients who completed study number CHL-AA-201.